MP31-02 SELECTIVE α1A-ADRENOCEPTOR BLOCKER SILODOSIN AMELIORATES VENTRAL PROSTATIC ENLARGEMENT IN THE SPONTANEOUSLY HYPERTENSIVE RAT : POSSIBLE ROLE OF THE PROSTATIC BLOOD FLOW

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Basic Research1 Apr 2015MP31-02 SELECTIVE α1A-ADRENOCEPTOR BLOCKER SILODOSIN AMELIORATES VENTRAL PROSTATIC ENLARGEMENT IN THE SPONTANEOUSLY HYPERTENSIVE RAT : POSSIBLE ROLE OF THE PROSTATIC BLOOD FLOW Shogo Shimizu, Panagiota Tsounapi, Takahiro Shimizu, Youichirou Higashi, Kumiko Nakamura, Felix Holmstrom, Masashi Honda, Keiji Inoue, and Motoaki Saito Shogo ShimizuShogo Shimizu More articles by this author , Panagiota TsounapiPanagiota Tsounapi More articles by this author , Takahiro ShimizuTakahiro Shimizu More articles by this author , Youichirou HigashiYouichirou Higashi More articles by this author , Kumiko NakamuraKumiko Nakamura More articles by this author , Felix HolmstromFelix Holmstrom More articles by this author , Masashi HondaMasashi Honda More articles by this author , Keiji InoueKeiji Inoue More articles by this author , and Motoaki SaitoMotoaki Saito More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1357AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A selective α1A-adrenoceptor blocker silodosin is known to increase the bladder blood flow in the spontaneously hypertensive rat (SHR), and consequently improve lower urinary tract symptoms. A decreased prostatic blood flow (PBF) could be one of the risk factors for benign prostatic enlargement (BPE). In the present study, the effect of silodosin was investigated in the SHR prostate as a BPE model. METHODS Twelve-week-old male SHRs were administered silodosin per orally (100, 300 μg/kg/day) once daily for 6 weeks. Wistar-kyoto (WKY) rats were used as normotensive controls. The control SHR and WKY rat groups were treated with vehicle. The effects of silodosin on blood pressure and PBF were estimated. Then, the tissue levels of oxidative stress marker (MDA), inflammatory cytokines (IL-6, CXCL1/CINC1 and TNF-α), and prostatic growth factors (TGF-β1, bFGF and α-SMA) were measured. The histological evaluation was performed by H&E staining. RESULTS There was a significant increase in blood pressure, MDA, IL-6, CXCL1/CINC1, TNF-α, TGF-β1, bFGF and α-SMA in the SHRs compared to WKY rats. On the other hand, the PBF was decreased in the SHRs. Moreover, the ventral prostate in the SHR group showed epithelial cells being taller in the shape. Both doses of silodosin significantly reversed the above parameters of SHRs to almost identical levels to the ones of the WKY group excluding the blood pressure. CONCLUSIONS A decreased PBF could induce the proliferative factors via release of oxidative stress and inflammatory cytokines in the SHR prostate. Silodosin may improve the BPE by increasing the PBF. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e355-e356 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shogo Shimizu More articles by this author Panagiota Tsounapi More articles by this author Takahiro Shimizu More articles by this author Youichirou Higashi More articles by this author Kumiko Nakamura More articles by this author Felix Holmstrom More articles by this author Masashi Honda More articles by this author Keiji Inoue More articles by this author Motoaki Saito More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...